| |
original article |
Journal |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
Regulatory Affairs Watch |
2022―Oct―29 |
Supporting research during the pandemic: How the Swiss National Science Foundation has responded to COVID-19 |
Irene Knüsel, Stéphanie Wyss, Pascal Walther, Marc Zbinden, Isabelle Guilleret, Marc Froissart |
| 2 |
[GO] |
Regulatory Affairs Watch |
2022―Oct―29 |
Patient organisations: COVID-19 concerns related to human research |
Isabelle Guilleret, Marc Froissart |
| 3 |
[GO] |
Regulatory Affairs Watch |
2022―Oct―29 |
Lessons learnt from the COVID-19 crisis: Regulatory aspects linked to human research and product authorisation |
Simone Ferbitz-Scheurer, Alexander Mion, Isabelle Guilleret, Marc Froissart |
| 4 |
[GO] |
Regulatory Affairs Watch |
2022―Oct―29 |
ECRIN’s and the SCTO’s roles as COVID-19 fosters innovation and catalyses cooperation amongst European clinical research actors |
Caecilia Schmid, Annette Magnin, Isabelle Guilleret, Marc Froissart |
| 5 |
[GO] |
Regulatory Affairs Watch |
2022―Oct―29 |
The role of swissethics and ethics committees during the COVID-19 pandemic |
Isabelle Guilleret, Marc Froissart |
| 6 |
[GO] |
Regulatory Affairs Watch |
2022―Oct―29 |
First lessons learnt about the regulatory aspects of human research related to COVID-19: Perspectives from the SCTO's Regulatory Affairs Platform |
Séverine Méance, Isabelle Guilleret, Marc Froissart |
| 7 |
[GO] |
Regulatory Affairs Watch |
2022―Oct―29 |
Human challenge studies in the time of COVID-19: Pros and cons |
Sonia Carboni, Isabelle Guilleret, Marc Froissart |
| 8 |
[GO] |
Regulatory Affairs Watch |
2022―Oct―29 |
Swiss participation in the WHO’s Solidarity trial to test the efficacy of repurposed drugs for treating COVID-19: What the research community has learnt so far |
Loane Warpelin-Decrausaz, Aurélie Fayet-Mello, Isabelle Guilleret, Marc Froissart |
